<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415645</url>
  </required_header>
  <id_info>
    <org_study_id>VVZ149-HMB-P1-US101</org_study_id>
    <nct_id>NCT04415645</nct_id>
  </id_info>
  <brief_title>Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects</brief_title>
  <official_title>Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Intravenous Dose of [14C]-VVZ-149 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivozon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivozon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study
      following a single IV infusion of [14C]-VVZ-149 in healthy adult male subjects. Whole blood,
      plasma, urine, and fecal samples will be analyzed for at least 72 hours following the start
      of infusion to measure total radioactivity and plasma drug concentrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance</measure>
    <time_frame>Day 15</time_frame>
    <description>Sum of the percent of the total radioactivity recovered in urine and feces relative to the administered radioactivity dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity (TRA) concentration equivalents in plasma</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRA concentration equivalents in urine</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRA concentration equivalents in feces</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentrations in plasma</measure>
    <time_frame>Hour 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-VVZ-149</intervention_name>
    <description>A single IV infusion of radio-labeled VVZ-149</description>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy, adult, male, 19-55 years of age, inclusive

          -  Continuous non-smoker

          -  BMI ≥ 18.0 and ≤ 32.0 kg/m2

          -  Medically healthy with no clinically significant medical history or findings

          -  Must agree to adhere to the contraception requirements

        Key Exclusion Criteria:

          -  History or presence of clinically significant medical or psychiatric condition or
             disease

          -  History or presence of alcohol or drug abuse within the past 2 years

          -  History, presence or evidence of cardiovascular, renal or hepatic impairment

          -  Less or abnormal bowel movements

          -  Unable to refrain from or anticipates the use of any prohibited drugs

          -  Recent donation of blood/plasma or significant blood loss

          -  Radiation exposure within 12 months

          -  Participation in another clinical study within 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

